News
How To Choose A Chemiluminescent Immunoassay Kit?
CLIA stands for chemiluminescent immunoassay. It is a technique used to detect and measure specific analytes in a biological sample. The analytes can be proteins, hormones, antibodies, antigens, cytokines, and other biomarkers. Like ELISA, it relies on antigen-antibody interactions....
News
Why Canada Keeps Running Out of Medications — and How Compounding Helps
Quick Answer
Canada runs short on medications because it imports roughly 90% of its prescription drugs, leaving the supply chain exposed to factory slowdowns, manufacturing problems, shipping delays, and sudden demand spikes. When a single overseas plant stalls, shelves empty...
News
How AI-Powered Imaging Systems Are Solving Healthcare’s Radiologist Shortage Crisis
Healthcare systems face growing imaging volumes and a limited number of radiology specialists to handle them. AI-powered imaging systems can help close this gap by streamlining routine tasks and giving radiologists more time for complex cases and clinical decisions....
Business & Industry
Eli Lilly’s $3.5 Billion Manufacturing Campus Advances in Upper Macungie, Pennsylvania
A planned $3.5 billion pharmaceutical manufacturing campus in Upper Macungie Township, Pennsylvania, has advanced through the local development process after the Upper Macungie Planning Commission recommended final subdivision and land development approval on August 19, 2026. Known as Project...
News
Overcoming Resistance-Associated Substitutions (RASs) to Direct-Acting Antivirals
Alt tag: Scientific illustration of Hepatitis C virus interacting with a human liver cell, showing host-targeting molecules disrupting viral entry, replication, and lipid-dependent assembly to overcome antiviral resistance.
While the introduction of Direct-Acting Antivirals has helped cure Hepatitis C, making...
News
Genentech Completes Structural Framework at New NC Manufacturing Facility
Genentech raised the final beam of its new Holly Springs, North Carolina manufacturing facility on August 18, marking the completion of the structural framework for what will become the company's first East Coast manufacturing site in the United States.
The...
Business & Industry
Chugai Pharmaceutical and GSK Sign Exclusive License Agreement for Anti-Dengue Antibody AID351
Japan-based Chugai Pharmaceutical has entered into an exclusive license agreement with British pharmaceutical company GlaxoSmithKline (GSK) for the anti-dengue virus antibody known as AID351, in a move that advances global efforts to combat one of the world's most widespread...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read